Department of Pediatric Dentistry, Kyung Hee University College of Dentistry, Kyung Hee University Medical Center, Seoul, Korea.
Department of Pediatric Dentistry, Kyung Hee University College of Dentistry, Kyung Hee University Medical Center, Seoul, Korea; Department of Pediatric Dentistry, School of Dentistry, Kyung Hee University, Seoul, Korea.
J Endod. 2024 Feb;50(2):235-242. doi: 10.1016/j.joen.2023.11.009. Epub 2023 Nov 22.
This study aimed to assess the biocompatibility and bioactivity of a dual-cured resin-based calcium silicate cement in vitro and in vivo.
For in vitro analyses, standardized samples were prepared using TheraCal LC, TheraCal PT, and ProRoot MTA. The amount of residual monomer released from TheraCal LC and TheraCal PT was assessed using liquid chromatography/mass spectrometry. Calcium ion release from the materials was evaluated using inductively coupled plasma-optical emission spectroscopy. Scanning electron microscopy and energy-dispersive X-ray spectroscopy were used to determine the calcium weight volume in the materials. For in vivo analysis, a rat direct pulp capping model with TheraCal LC, TheraCal PT, and ProRoot MTA groups (n = 16 per group) was used. The rats were euthanized after 7 or 28 days, and histological and immunohistochemical analyses (CD68 and DSPP) were performed.
Bisphenol A-glycidyl methacrylate and polyethylene glycol dimethacrylate release from TheraCal PT was lower than that from TheraCal LC (P < .05). Similar results were obtained for calcium-ion release and calcium weight volume, with ProRoot MTA showing the highest values. In the in vivo evaluation, TheraCal PT showed significantly greater hard tissue formation than TheraCal LC (P < .017). TheraCal PT showed lower CD68 expression and greater DSPP expression than TheraCal LC (P < .017). There were no significant differences in the expression of CD68 or DSPP between the TheraCal PT and ProRoot MTA groups.
Within the limitations of this study, the biocompatibility and bioactivity of TheraCal PT could be comparable to those of ProRoot MTA.
本研究旨在评估一种双固化树脂基硅酸钙水泥的体外和体内生物相容性和生物活性。
对于体外分析，使用 TheraCal LC、TheraCal PT 和 ProRoot MTA 制备标准化样品。使用液相色谱/质谱法评估 TheraCal LC 和 TheraCal PT 释放的残留单体量。使用电感耦合等离子体-光学发射光谱法评估材料中钙离子的释放。扫描电子显微镜和能量色散 X 射线光谱用于确定材料中的钙重量体积。对于体内分析，使用 TheraCal LC、TheraCal PT 和 ProRoot MTA 组的大鼠直接牙髓盖髓模型（每组 n = 16）。大鼠在 7 或 28 天后安乐死，并进行组织学和免疫组织化学分析（CD68 和 DSPP）。
TheraCal PT 中的双酚 A-缩水甘油甲基丙烯酸酯和聚乙二醇二甲基丙烯酸酯释放低于 TheraCal LC（P<.05）。对于钙离子释放和钙重量体积，也得到了类似的结果，ProRoot MTA 表现出最高的值。在体内评估中，TheraCal PT 显示出比 TheraCal LC 更显著的硬组织形成（P<.017）。TheraCal PT 显示出比 TheraCal LC 更低的 CD68 表达和更高的 DSPP 表达（P<.017）。TheraCal PT 和 ProRoot MTA 组之间的 CD68 或 DSPP 表达没有显著差异。
在本研究的限制范围内，TheraCal PT 的生物相容性和生物活性可以与 ProRoot MTA 相媲美。
